Hainan Shuangcheng Pharmaceut (002693) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.083x

Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.67 Million ≈ $4.93 Million USD) by net assets (CN¥404.35 Million ≈ $59.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hainan Shuangcheng Pharmaceut liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Hainan Shuangcheng Pharmaceut - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Hainan Shuangcheng Pharmaceut's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hainan Shuangcheng Pharmaceut Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
PDS Limited
NSE:PDSL
-0.080x
Beijing Career International Co Ltd
SHE:300662
0.059x
Indigo Paints Limited
NSE:INDIGOPNTS
0.027x
Duratec Ltd
AU:DUR
0.111x
Serve Robotics Inc. Common Stock
NASDAQ:SERV
-0.130x
Shenzhen Asiantime International Construction Co Ltd
SHE:002811
0.071x
Viyash Scientific Limited
NSE:SEQUENT
0.051x
Gazit Globe Ltd
TA:GZT
0.007x

Annual Cash Flow Conversion Efficiency for Hainan Shuangcheng Pharmaceut (2009–2025)

The table below shows the annual cash flow conversion efficiency of Hainan Shuangcheng Pharmaceut from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 002693 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥420.53 Million
≈ $61.54 Million
CN¥60.95 Million
≈ $8.92 Million
0.145x +246.12%
2024-12-31 CN¥411.61 Million
≈ $60.23 Million
CN¥-40.83 Million
≈ $-5.97 Million
-0.099x -541.12%
2023-12-31 CN¥517.65 Million
≈ $75.75 Million
CN¥11.64 Million
≈ $1.70 Million
0.022x -48.20%
2022-12-31 CN¥580.94 Million
≈ $85.01 Million
CN¥25.22 Million
≈ $3.69 Million
0.043x +4.45%
2021-12-31 CN¥566.75 Million
≈ $82.93 Million
CN¥23.55 Million
≈ $3.45 Million
0.042x +336.77%
2020-12-31 CN¥598.31 Million
≈ $87.55 Million
CN¥-10.50 Million
≈ $-1.54 Million
-0.018x -117.88%
2019-12-31 CN¥678.26 Million
≈ $99.25 Million
CN¥66.58 Million
≈ $9.74 Million
0.098x +40.36%
2018-12-31 CN¥669.69 Million
≈ $98.00 Million
CN¥46.84 Million
≈ $6.85 Million
0.070x +336.39%
2017-12-31 CN¥761.71 Million
≈ $111.46 Million
CN¥-22.54 Million
≈ $-3.30 Million
-0.030x -142.35%
2016-12-31 CN¥553.13 Million
≈ $80.94 Million
CN¥38.65 Million
≈ $5.66 Million
0.070x +40.17%
2015-12-31 CN¥927.61 Million
≈ $135.74 Million
CN¥46.24 Million
≈ $6.77 Million
0.050x -12.67%
2014-12-31 CN¥893.55 Million
≈ $130.75 Million
CN¥51.00 Million
≈ $7.46 Million
0.057x -11.95%
2013-12-31 CN¥870.62 Million
≈ $127.40 Million
CN¥56.43 Million
≈ $8.26 Million
0.065x -31.65%
2012-12-31 CN¥845.85 Million
≈ $123.77 Million
CN¥80.22 Million
≈ $11.74 Million
0.095x -67.23%
2011-12-31 CN¥228.23 Million
≈ $33.40 Million
CN¥66.05 Million
≈ $9.67 Million
0.289x -17.45%
2010-12-31 CN¥157.82 Million
≈ $23.09 Million
CN¥55.33 Million
≈ $8.10 Million
0.351x -38.27%
2009-12-31 CN¥77.95 Million
≈ $11.41 Million
CN¥44.27 Million
≈ $6.48 Million
0.568x --

About Hainan Shuangcheng Pharmaceut

SHE:002693 China Drug Manufacturers - Specialty & Generic
Market Cap
$529.15 Million
CN¥3.62 Billion CNY
Market Cap Rank
#12076 Global
#3511 in China
Share Price
CN¥8.72
Change (1 day)
-1.13%
52-Week Range
CN¥6.52 - CN¥11.61
All Time High
CN¥38.37
About

Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more